Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on Tandem Diabetes Care with a $45 price target.
September 23, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley's analyst Patrick Wood has reiterated an Equal-Weight rating for Tandem Diabetes Care, maintaining a price target of $45. This suggests a neutral stance on the stock's potential performance.
The reiteration of an Equal-Weight rating and a maintained price target of $45 by Morgan Stanley indicates a neutral outlook on Tandem Diabetes Care's stock. This suggests that the analyst does not foresee significant upside or downside in the short term, which is likely to result in a stable stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100